Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective study
Kazuhiro Takahashi, Fumihiko Urabe, Yushi Suhara, Juria Nakano, Kentaro Yoshihara, Yuma Goto, Ibuki Sadakane, Yuhei Koike, Yuji Yata, Hirotaka Suzuki, Shiro Kurawaki, Keiichiro Miyajima, Kosuke Iwatani, Yu Imai, Keigo Sakanaka, Minoru Nakazono, Takashi Kurauchi, Sotaro Kayano, Hajime Onuma, Koichi Aikawa, Takafumi Yanagisawa, Kojiro Tashiro, Shunsuke Tsuzuki, Yusuke Koike, Akira Furuta, Jun Miki, Takahiro Kimura
Abstract
BACKGROUND: Multiple studies have demonstrated the effectiveness of neoadjuvant chemotherapy and adjuvant chemotherapy in patients with upper tract urothelial carcinoma compared with surgery alone. However, no clinical trial has established the superiority of neoadjuvant chemotherapy or adjuvant chemotherapy in terms of perioperative outcomes. METHODS: We conducted a retrospective analysis encompassing 164 upper tract urothelial carcinoma patients who underwent radical nephroureterectomy and received perioperative chemotherapy. Of these patients, 65 (39.6%) and 99 (60.4%) received neoadjuvant chemotherapy and adjuvant chemotherapy, respectively. Recurrence-free survival and cancer-specific survival were computed using the Kaplan-Meier method. Additionally, we conducted Cox regression analyses to evaluate the risk factors for recurrence-free survival and cancer-specific survival. RESULTS: Pathological downstaging was seen in 37% of the neoadjuvant chemotherapy group. However, no pathological complete response was observed in this cohort. The Kaplan-Meier curves demonstrated significantly lower recurrence-free survival and cancer-specific survival in patients who received adjuvant chemotherapy. Multivariate Cox regression analysis revealed patients treated with adjuvant chemotherapy exhibited a marked association with inferior recurrence-free survival and cancer-specific survival. CONCLUSION: Our study has suggested that neoadjuvant chemotherapy would be more effective in high-risk upper tract urothelial carcinoma patients compared with adjuvant chemotherapy.